← back to search

Nathalie Chaput

Inserm · FR
Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Immune Cell Function and Interaction, and CAR-T cell therapy research.
h-index
67
citations
27,583
works
452
NIH funding
primary concept
Medicine
email

Recent publications

Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
Cancer Discovery 2023cited by 26position: middledoi
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
European Journal of Cancer 2022cited by 156position: middledoi
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
European Journal of Cancer 2021cited by 60position: middledoi
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
JAMA Oncology 2018cited by 944position: middledoi
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Science 2015cited by 3,371position: middledoi
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Journal of Extracellular Vesicles 2015cited by 1,491position: middledoi
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC
OncoImmunology 2015cited by 778position: lastdoi
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Cell Research 2015cited by 159position: middledoi
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients
Science Translational Medicine 2015cited by 143position: middledoi
Erratum: Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Cell Research 2015cited by 133position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Édouard Auclin · Inserm1 papers (2018–2018) · 1 papers (2018–2018) · 1 papers (2018–2018)Pilar Garrido · Hospital Universitario Ramón y Cajal1 papers (2018–2018)Julien Mazières · Université Toulouse III - Paul Sabatier1 papers (2018–2018)Jordi Remón · Delfos Hospital1 papers (2018–2018)Gérard Zalcman · Grenoble Institute of Neurosciences1 papers (2018–2018) · 1 papers (2018–2018)Luis Paz Ares · Hospital Universitario HM Madrid1 papers (2018–2018) · 1 papers (2018–2018)Solenn Brosseau · Université Claude Bernard Lyon 11 papers (2018–2018)Enriqueta Felip · Université Grenoble Alpes1 papers (2018–2018)Roberto Ferrara · University of Iowa1 papers (2018–2018)Jean Charles Soria · Amgen (United States)1 papers (2018–2018)Santiago Ponce · University of Southern California1 papers (2018–2018)Clarisse Audigier-Valette · Université de Toulon1 papers (2018–2018)Julien Adam · Institut Gustave Roussy1 papers (2018–2018)Laura Mezquita · Université Paris-Saclay1 papers (2018–2018)Benjamin Besse · Institut Gustave Roussy1 papers (2018–2018) · 1 papers (2018–2018)